Overview
- A peer‑reviewed study published in mid‑June 2026 found that nursing‑facility residents who received at least one dose of the recombinant shingles vaccine Shingrix had a 24 percent lower risk of a dementia diagnosis over four years compared with unvaccinated residents.
- The analysis used Medicare claims and electronic health records for more than 500,000 adults aged 66 and older admitted to over 5,500 U.S. skilled nursing facilities between 2017 and 2022 and applied a target‑trial emulation method to approximate a randomized comparison.
- Vaccination uptake in the cohort was very low, with only 8,843 of 509,926 participants receiving Shingrix, which limits how broadly the result can be generalized and reduces statistical power for some subgroup comparisons.
- Study authors and external experts caution that vaccinated people tended to be slightly younger and healthier and that residual confounding cannot be ruled out, so the association should not be read as proof of causation without randomized trials.
- Researchers point to plausible mechanisms such as preventing varicella‑zoster virus linked neuroinflammation or vascular damage and say the results justify clinical trials and further biological study while clinicians continue to recommend Shingrix for proven shingles prevention; the study disclosed funding from GSK with the authors reporting the company had no control over design or analysis.